test

CPX-351 IN PATIENTS 60-75 YEARS OF AGE WITH AML

Conditions

Leukemia, other

What is the purpose of this trial?

To confirm the efficacy of CPX-351 compared to (7+3) as first line therapy in elderly patients (60-75 years) with high risk (secondary) AML. The primary efficacy endpoint will be overall survival.


Participation Guidelines

Age:
60 Years and older
Gender:
Both

Click here for detailed information about who can participate in this trial.


Sponsor:
Celator Pharmaceuticals, Inc.
Dates:
07/30/2014
Last Updated:
Study HIC#:
1403013666